Thus, further studies are warranted to determine whether intravenously infused ABCB5+ MSCs, at currently explored doses, are indeed capable of replacing defective collagen VII in RDEB skin at rates that could potentially confer therapeutic benefits. This evidence concerns the gene ABCB5 and recessive dystrophic epidermolysis bullosa.